# A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Source: https://onco.cc/trials/aspen-06/  
OnCo record `aspen-06` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial testing Evorpacept in gastric & gastro-oesophageal junction cancer, active and no longer recruiting.

## Summary

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) is a phase 2/3 interventional study registered as NCT05002127, led by ALX Oncology with Eli Lilly and, and active but no longer recruiting on the registry. Official title: A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06). Planned enrolment is 127 participants (actual). The study started in 2022-01-15 and primary completion is expected in 2024-05-24. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: ASPEN-06
- Tags: ctgov-ingest
- Registry id: NCT05002127
- Phase: 2/3
- Setting: A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
- Sponsor: ALX Oncology
- Enrolled: 127

## Sources

- ClinicalTrials.gov NCT05002127: https://clinicaltrials.gov/study/NCT05002127

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/)
- technologies: [CD47 and SIRP-alpha blockade](https://onco.cc/technologies/cd47-blockade/)
- drugs: [Evorpacept](https://onco.cc/drugs/evorpacept/)
- companies: [ALX Oncology](https://onco.cc/companies/alx-oncology/)
- terms: [Seamless, adaptive and Bayesian trial designs](https://onco.cc/terms/seamless-adaptive/)

---
JSON: https://onco.cc/api/v1/entities/aspen-06.json